Emerging Technology: Page 2

Analysis: Biomarker testing and targeted therapy underutilized in U.S. NSCLC patients
By LabPulse.com staff writers
Biomarker testing and targeted therapy is significantly underused for patients with non-small cell lung cancer (NSCLC) in the U.S., according to an analysis of point-of-care real-world data conducted by Amplity Health.
June 10, 2024
Artificial Intelligence Lung Color Social
Bruker launches new tissue imaging system at ASMS 2024
By LabPulse.com staff writers
Bruker Corporation has launched its MALDI-TOF/TOF Neoflex Imaging Profiler for mass spectrometry-based tissue imaging, unveiling the new system at the 72nd ASMS meeting.
June 6, 2024
Modern Lab Equipment Social
Tempus introduces HER2 and FOLR1 tests for solid tumor cancers
By LabPulse.com staff writers
Precision medicine firm Tempus has launched two new tests to help identify patients with HER2- or FOLR1-expressing tumors who may be eligible for targeted therapies such as antibody-drug conjugates.
June 3, 2024
Cancer Therapy Targeted Social
Pillar Biosciences gets FDA approval for NGS solid tumor profiling test
By Matt Limb
Pillar Biosciences has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its OncoReveal CDx pan-cancer next-generation sequencing (NGS) test for general solid tumor profiling.
April 26, 2024
Fda Button Social
Roche's breast cancer CDx receives CE Mark
By LabPulse.com staff writers
Roche has received the CE Mark for the first companion diagnostic (CDx) test to identify patients with HER2-low metastatic breast cancer who may be eligible for treatment with Enhertu.
April 10, 2024
Breast Mammo Social
FDA clears another blood-based TBI POC test
By LabPulse.com staff writers
Abbott furthers its point-of-care (POC) assay for measuring traumatic brain injury biomarkers from whole blood.
April 1, 2024
Brain Abstract Social
Researchers map protein biomarkers in sepsis fight
By Liz Carey
Swedish researchers are mapping patterns of protein biomarkers in sepsis that could be useful for simple blood tests in the emergency department, according to research to be presented at ECCMID 2024.
April 2, 2024
Sepsis Bacteria Social
Eventually, an oral cancer diagnosis may be a lick away
By Melissa Busch
The University of Birmingham in the U.K. will develop a new, noninvasive way to diagnose mouth cancer that has a sweet twist.
March 28, 2024
Lollipop
Metabolon releases integrated bioinformatics platform
By Matt Limb
Metabolon has launched an integrated bioinformatics platform to aid metabolomics analysis in life sciences research.
March 12, 2024
Laboratory Software Social
FDA LDT oversight battle: Are we close?
By Liz Carey
New directions in laboratory developed test (LDT) regulation appeared closer to final rule-making with the March 1 Office of Management and Budget (OMB) acceptance of the LDT final rule, pending regulatory review: a flurry of final rule-making thoughts.
March 6, 2024
Omb Final Rule Laboratory Developed Tests March124
Alamar Biosciences raises $100M in series C financing round
By LabPulse.com staff writers
Precision proteomics company Alamar Biosciences has raised $100 million in an oversubscribed series C financing round, with a second close of an additional $28 million anticipated within the next 30 days.
February 27, 2024
Money Hundred Bills Social
Gold-enhanced nanopore sensors detect ovarian cancer biomarker in urine
By Nick Paul Taylor
Nanopore sensors that use gold nanoparticles to capture certain peptides could enable the detection of ovarian cancer biomarkers in urine samples, according to a paper published in ACS Sensors.
February 14, 2024
Ovarian Cancer2 Social
Previous Page
Page 2 of 52
Next Page